59

DAFTAR PUSTAKA

Abdullah FN, Jaya AS, dan Widayat, 2017. Penentuan waktu perendaman sel (fase
mitosis) akar bawang merah (Allium ascalonicum L.) menggunakan safranin
untuk mendukung praktikum biologi, Bioleuser, vol. 1, no. 2, pp. 86–91.
Alamsyah F, Ajrina IN, Dewi FNA, Iskandriati D, Prabandari SA, Taruno WP, 2017.
Antiproliferative Effect of Electric Fields on Breast Tumor Cells In Vitro and
In Vivo, Indonesian Journal of Cancer Chemoprevention, vol. 6, no. 3, pp. 71.
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, 2002. An Overview of
the Cell Cycle, in Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter
P (ed.), Molecular Biology of the Cell, 4th edn, Garland Science, New York.
Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A, 2015.
Glioblastoma: pathology, molecular mechanisms and markers, Acta
Neuropathologica, vol. 129, no. 6, pp. 829–848.
Alifieris C, Trafalis D, 2015. Glioblastoma multiforme: Pathogenesis and treatment,
Pharmacol Ther, vol. 152, pp. 63–82.
Andiani L, Huda M, Taruno WP, 2017. A Novel Method For Analyzing Electric
Field Distribution Of Electro Capacitive Cancer Treatment (ECCT) Using
Wire Mesh Electrodes : A Case Study Of Brain Cancer Therapy,
Euromediterranean Biomedical Journal, vol. 12, no. 38, pp. 178–183.
Angulo MC, 2004. Glutamate Released from Glial Cells Synchronizes Neuronal
Activity in the Hippocampus, Journal of Neuroscience, vol. 24, no. 31, pp.
6920–6927.
von Bartheld CS, Bahney J, Herculano-Houzel S, 2016. The search for true numbers
of neurons and glial cells in the human brain: A review of 150 years of cell
counting, Journal of Comparative Neurology, vol. 524, no. 18, pp. 3865–
3895.
Bendris N, Lemmers B, Blanchard J, Arsic N, 2011. Cyclin A2 mutagenesis analysis:
A new insight into CDK activation and cellular localization requirements,
PLoS ONE, vol. 6, no. 7.
Bonert M, 2011. Glioblastoma, diunduh 15 September 2019,
<https://librepathology.org/wiki/File:Glioblastoma_-_high_mag.jpg>.
Branter J, Basu S, Smith S, 2018. Tumour treating fields in a combinational
therapeutic approach, Oncotarget, vol. 9, no. 93.
Brat DJ, Prayson RA, Ryken TC, Olson JJ, 2008. Diagnosis of malignant glioma:
Role of neuropathology, Journal of Neuro-Oncology, vol. 89, no. 3, pp. 287–
311.
Bratton SB, Salvesen GS, 2010. Regulation of the Apaf-1-caspase-9 apoptosome,
Journal of Cell Science, vol. 123, no. 19, p. 3209–3214.
Brecht S, Gelderblom M, Srinivasan A, Mielke K, Dityateva G, Herdegen T, 2001.
Caspase-3 activation and DNA fragmentation in primary hippocampal
neurons following glutamate excitotoxicity, Molecular Brain Research, vol.
94, pp. 25–34.
60

Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH, 2009.

Glioblastoma Multiforme in the Posterior Cranial Fossa in a Patient with
Neurofibromatosis Type I, Case Reports in Medicine, pp. 1–4.
Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel
AS, Rizk EB, Suki D, Sawaya R, Glantz M, 2016. Association of the Extent
of Resection With Survival in Glioblastoma: A Systematic Review and Meta-
analysis, JAMA Oncology, vol. 2, no. 11, pp. 1460–1469.
Butters JT, Figueroa XA, Butters BM, 2014. Non-Thermal Radio Frequency
Stimulation of Tubulin Polymerization in Vitro: A Potential Therapy for
Cancer Treatment, Open Journal of Biophysics, vol. 04, no. 04, pp. 147–168.
Central Brain Tumor Registry of The United States, 2018. 2018 CBTRUS Fact Sheet,
diunduh 1 Agustus 2019, <http://www.cbtrus.org/factsheet/factsheet.html>
Cha S, Lupo JM, Chen MH, Lamborn KR, McDermott MW, Berger MS, Nelson SJ,
Dillon WP, 2007. Differentiation of glioblastoma multiforme and single brain
metastasis by peak height and percentage of signal intensity recovery derived
from dynamic susceptibility-weighted contrast-enhanced perfusion MR
imaging, American Journal of Neuroradiology, vol. 28, no. 6, pp. 1078–1084.
Chaichana KL, Jusue-Torres I, Lemos AM, Gokaslan A, Cabrera-Aldana EE, Ashary
A, Olivi A, Quinones-Hinojosa A, 2014. The butterfly effect on glioblastoma:
is volumetric extent of resection more effective than biopsy for these tumors?,
Journal of Neuro-Oncology, vol. 120, no. 3, pp. 625–634.
Chen J, 2016. The Cell-Cycle Arrest and Apoptotic and Progression, Cold Spring
Harbor perspectives in biology, vol. 6, no. 3, pp. 1–16.
Chen J, McKay R, Parada L, 2012. Malignant glioma: lessons from genomics, mouse
models, and stem cells, Cell, vol. 149, no. 1, p. 36–47.
Clute P, Pines J, 1999. Temporal and spatial control of cyclin B1 destruction in
metaphase, Nature Cell Biology, vol. 1, no. 2, pp. 82–87.
Cobbs CS, 2011. Evolving evidence implicates cytomegalovirus as a promoter of
malignant glioma pathogenesis, Herpesviridae, vol. 2, no. 1, pp. 10.
Cooper G, 2000a. The Eukaryotic Cell Cycle, in Cooper G (ed.) The Cell: A
Molecular Approach, 2nd edn, Sinauer Associates, Sunderland (MA).
Cooper G, 2000b. The Events of M Phase, in Cooper G (ed.) The Cell: A Molecular
Approach, 2nd edn, Sinauer Associates, Sunderland (MA).
Cory S, Huang D, Adams JM, 2003. Oncogene Bcl2 Family, Oncogene, vol. 22, no.
53, pp. 8590–8607.
Costa B, Bendinelli S, Gabelloni P, Da Pozzo E, Daniele S, Scatena F, Vanacore R,
Campiglia P, Bertamino A, Gomez-Monterrey I, Sorriento D, Del Giudice C,
Iaccarino G, Novellino E, Martini C, 2013. Human glioblastoma multiforme:
P53 reactivation by a novel MDM2 inhibitor, PLoS ONE. Public Library of
Science, vol. 8, no. 8.
CTech Labs, 2014. Efektifitas Electro-Capacitive Cancer Treatment (ECCT) untuk
Kanker Otak, diunduh pada 15 September 2019, <http://www.c-
techlabs.com/efektifitas-electro-capacitive-cancer-treatment-ecct-untuk-
kanker-otak/>.
61

Coverley D, Laman H, Laskey RA, 2002. Distinct roles for cyclins E and A during
DNA replication complex assembly and activation, Nature Cell Biology, vol.
4, no. 7, pp. 523–528.
Czabotar P, Wetphal D, Dewson G, Ma S, Hockings C, Fairlie WD, Lee EF, Yao S,
Robin AY. SMith BJ, Huang DC, Kluck RM, Adams JM, Colman PM, 2012.
Bax crystal structures reveal how BH3 domains activate Bax and nucleate its
oligomerization to induce apoptosis, Cell, vol. 152, pp. 519–531.
D'Sa-Eipper C, Leonard JR, Putcha G, Zheng TS, Flavell RA, Rakic P, Kuida K,
Roth KA, 2001. DNA damage-induced neural precursor cell apoptosis
requires p53 and caspase 9 but neither Bax nor caspase 3, Development,
128(1), pp. 137–146.
Davies AM, Weinberg U, Palti Y, 2013. Tumor treating fields: A new frontier in
cancer therapy, Annals of the New York Academy of Sciences, vol. 1291, no.
1, pp. 86–95.
Davis M, 2016. Glioblastoma: Overview of Disease and Treatment, Clin J Oncol
Nurs, vol. 20, no. 5, pp. S2–S8.
Dayani F, Young JS, Bonte A, Chang EF, Theodosopoulos P, McDermott MW,
Berger MS, Aghi MK, 2018. Safety and outcomes of resection of butterfly
glioblastoma, Neurosurgical Focus, vol. 44, no. 6, pp. E4.
Diao W, Tong X, Yang C, Zhang F, Bao C, Chen H, Liu L, Li M, Ye F, Fan Q, Wang
J, Ou-Yang Z, 2019. Behaviors of Glioblastoma Cells in in Vitro
Microenvironments, Scientific Reports, vol. 9, no. 1, pp. 1–9.
Duzgun Z, Eroglu Z, Biray Avci C, 2016. Role of mTOR in glioblastoma, Gene, vol.
575, no. 2, pp. 187–190.
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H,
Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA,
Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS,
Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC,
Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD,
Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB, 2015. Glioma groups
based on 1p/19q, IDH, and TERT promoter mutations in tumors, New
England Journal of Medicine, vol. 372, no. 26, pp. 2499–2508.
Ellor S, Pagano-Young T, Avgeropoulos N, 2014. Glioblastoma: background,
standard treatment paradigms, and supportive care considerations, J Law Med
Ethics, vol. 42, no. 2, pp. 171–82.
Elmore S, 2007. Apoptosis: A Review of Programmed Cell Death, Toxicologic
Pathology, vol. 35, no. 4, pp. 495–516.
Engelhard HH, Vilano JL, Porter KR, Stewart AK, Barua M, Barker FG, Newton HB,
2010. Clinical presentation, histology, and treatment in 430 patients with
primary tumors of the spinal cord, spinal meninges, or cauda equina, Journal
of Neurosurgery: Spine, vol. 13, no. 1, pp. 67–77.
Eseonu CI, Rincon-Torroella J, ReFaey K, Lee YM, Nangiana J, Vivas-Buitrago T,
Quiñones-Hinojosa A, 2017. Awake Craniotomy vs Craniotomy Under
General Anesthesia for Perirolandic Gliomas: Evaluating Perioperative
62

Complications and Extent of Resection, Neurosurgery, vol. 81, no. 3, pp. 481–
489.
Fan QW, Weiss WA, 2012. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma
by mTORC1/2 inhibitors, Methods in Molecular Biology, vol. 821, pp. 349–
359.
Fletcher GC, Xue L, Passingham SK, Tolkovsky AM, 2000. Death commitment point
is advanced by axotomy in sympathetic neurons, J Cell Biol, vol. 150, pp.
741–754.
Fricker M, Tolkovsky AM, Borutaite V, Coleman M, Brown GC, 2018. Neuronal
Cell Death, Physiol Rev, vol. 98, pp. 813–880.
Gupta A, Dwivedi T, 2017. A Simplified Overview of World Health Organization
Classification Update of Central Nervous System Tumors 2016, J Neurosci
Rural Pract., vol. 8, no. 4, pp. 629–641.
Haase G, Pettmann B, Raoul C, Hendrson CE, 2008. Signaling by death receptors in
the nervous system, Curr Opin Neurobiol, vol. 18, pp. 284–291.
Hagting A, Den Elzen N, Vodermaier HC, Waizenegger IC, Peters JM, Pines J, 2002.
Human securin proteolysis is controlled by the spindle checkpoint and reveals
when the APC/C switches from activation by Cdc20 to Cdh1, The Journal of
Cell Biology, vol. 157, no. 7, pp. 1125–1137.
Haj A, Doenitz C, Schebesch K, Ehrensberger D, Hau P, Putnik K, Riemenschneider
MJ, Wendl C, Gerken M, Pukrop T, Brawanski A, Proescholdt MA, 2017.
Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a
Specialized Neuro-Oncology Care Center, Brain sciences, vol. 8, no. 1, pp. 5.
Handayani YK, 2012. Efektivitas Penggunaan Electro Capacitive Cancer (ECCT)
dalam Terapi Kanker Payudara, skripsi, Universitas Indonesia, Jakarta.
Handriyanto M, 2013. Efektivitas electro capacitive cancer treatment (ecct) untuk
kanker otak, skripsi, Universitas Indonesia, Jakarta.
Haschka M, Karbon M, Fava LL, Villunger A, 2018. Perturbing mitosis for anti‐
cancer therapy: is cell death the only answer?, EMBO reports, vol. 19, no. 3,
pp. 1–20.
Hauf S, Waizenegger IC, Peters JM, 2001. Cohesin Cleavage by Separase Required
for Anaphase and Cytokinesis in Human Cells, Science, vol. 293, no, 5533,
pp. 1320–1323.
Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S, 2000.
Expression of pituitary-tumour transforming gene in colorectal tumours, The
Lancet, vol. 355, no. 9205, pp. 716–719.
Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA, 1992.
Regulation of retinoblastoma protein functions by ectopic expression of
human cyclins, Cell, vol. 70, no. 6, pp. 993–1006.
Hinz M, Scheidereit C, 2014. The IκB kinase complex in NF-κB regulation and
beyond, EMBO Reports, pp. 46–61.
Hottinger AF, Pacheco P, Stupp R, 2016. Tumor treating fields: A novel treatment
modality and its use in brain tumors, Neuro-Oncology, pp. 1338–1349.
Israël A, 2010. The IKK complex, a central regulator of NF-kappaB activation, Cold
Spring Harb Perspect Biol, vol. 2, no. 3, pp. a000158.
63

Itakura H, Achrol AS, Mitchell LA, Loya JJ, Liu T, Westbroek EM, Feroze AH,
Rodriguez S, Echegaray S, Azad TD, Yeom KW, Napel S, Rubin DL, Chang
SD, Harsh GR, Gevaert O, 2015. Magnetic resonance image features identify
glioblastoma phenotypic subtypes with distinct molecular pathway activities,
Sci Transl Med, vol. 7, no. 303, pp. 303ra138.
Jakobson M, Jakobson M, Llano O, Palgi J, Arumäe U, 2013. Multiple mechanisms
repress N-Bak mRNA translation in the healthy and apoptotic neurons, Cell
Death Dis, vol. 4, pp. e777.
Janbazian L, Karamchandani J, Das S, 2014. Mouse models of glioblastoma: Lessons
learned and questions to be answered, Journal of Neuro-Oncology, vol. 118,
no. 1, pp. 1–8.
Jiang X, Jiang H, Shen Z, Wang X, 2014. Activation of mitochondrial protease
OMA1 by Bax and Bak promotes cytochrome c release during apoptosis, Proc
Natl Acad Sci USA, vol. 111, pp. 14782–14787.
de Jong D, Prins FA, Mason DY, Reed JC, van Ommen GB, Kluin PM, 1994.
Subcellular localization of the bcl-2 protein in malignant and normal
lymphoid cells, Cancer research, vol. 54, no. 1, pp. 256–60.
Jung T, Jung S, 2007. Early Neuroimaging Findings of Glioblastoma Mimicking
Non-neoplastic Cerebral Lesion, Neurol Med Chir (Tokyo), vol. 47, no. 9, pp.
424–427.
Kanungo AK, Hao Z, Elia AJ, Mak TW, Henderson JT, 2008. Inhibition of
apoptosome activation protects injured motor neurons from cell death, J Biol
Chem, vol. 283, pp. 22105–22112.
Karch J, Molkentin JD, 2015. Regulated necrotic cell death: The passive aggressive
side of bax and bak, Circulation Research, vol. 116, no. 11, pp. 1800–1809.
Karin M, Delhase M, 2000. The I kappa B kinase (IKK) and NF-kappa B: key
elements of proinflammatory signalling, Semin Immunol, vol. 12, no. (1), pp.
85–98.
Kazda T, Dziacky A, Burkon P, Pospisil P, Slavik M, Rehak Z, Jancalek R, Slampa
P, Slaby O, Lakomy R, 2018. Radiotherapy of glioblastoma 15 years after the
landmark Stupp’s trial: More controversies than standards?, Radiology and
Oncology, vol. 52, no. 2, pp. 121–128.
Kijima N, Kanemura Y, 2017. Mouse Models of Glioblastoma, in De Vleeschouwer
S (ed.) Glioblastoma. Codon Publications, Brisbane (AU).
Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, Torikoshi Y,
Tanaka S, Yoshida T, Ishihara H, Noguchi S, 2008. Determination of the
specific activity of CDK1 and CDK2 as a novel prognostic indicator for early
breast cancer, Annals of oncology : official journal of the European Society
for Medical Oncology / ESMO, vol. 19, no. 1, pp. 68–72.
Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y,
Schatzberger R, Palti Y, 2004. Disruption of Cancer Cell Replication by
Alternating Electric Fields, Cancer Research, vol. 64, pp. 3288–3295.
Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D,
Steinberg-SHapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg
M, Ryffel B, Goldsher D, Dekel E, Palti Y, 2007. Alternating electric fields
64

arrest cell proliferation in animal tumor models and human brain tumors,
Proceedings of the National Academy of Sciences of the United States of
America, vol. 104, no. 24, pp. 10152–10157.
Kirson ED, Schneiderman RS, Dbalý V, Tovarys F, Vymazal J, Itzhaki A,
Mordechovich D, Gurvich Z, Shmueli E, Goldsher D, Wasserman Y, Palti Y,
2009. Chemotherapeutic treatment efficacy and sensitivity are increased by
adjuvant alternating electric fields (TTFields), BMC Medical Physics, vol. 9,
no. 1, pp. 1–13.
Kostaras X, Cusano F, Kline GA, Roa W, Easaw J, 2014. Use of dexamethasone in
patients with high-grade glioma: A clinical practice guideline, Current
Oncology, vol. 21, no. 3, pp. 493–503.
Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS,
2015. Descriptive epidemiology of World Health Organization grades II and
III intracranial meningiomas in the United States, Neuro-Oncology, vol. 17,
no. 8, pp. 1166–1173.
Lara-Gonzalez P, Westhorpe FG, Taylor SS, 2012. The Spindle Assembly
Checkpoint, Current Biology, vol. 22, no. 22, pp. R966–R980.
Lara-Velazquez M, Al-Kharboosh R, Jeanneret S, Vazquez-Ramos C, Mahato D,
Tavanaiepour D, Rahmathulla G, Quinones-Hinojosa A, 2017. Advances in
brain tumor surgery for glioblastoma in adults, Brain Sciences, vol. 7, no. 12,
pp. 1–16.
Li M, Zhang P, 2009. The function of APC/CCdh1 in cell cycle and beyond, Cell
Division, vol. 4, no. 1, pp. 2.
Lindqvist A, van Zon W, Rosenthal CK, Wolthuis RMF, 2007. Cyclin B1-Cdk1
activation continues after centrosome separation to control mitotic
progression, PLoS Biology, vol. 5, no. 5, pp. 1127–1137.
Liu A, Hou C, Chen H, Zong X, Zong P, 2016. Genetics and Epigenetics of
Glioblastoma: Applications and Overall Incidence of IDH1 Mutation,
Frontiers in Oncology, vol. 6(January), pp. 1–9.
Lodish H, Berk A, Zipursky L, Matsudaira P, Baltimore D, Darnell J, 2000.
Molecular Cell Biology, 4th edn, W.H. Freeman, New York.
Lok E, San P, Hua V, Phung M, Wong ET, 2017. Analysis of physical characteristics
of Tumor Treating Fields for human glioblastoma, Cancer medicine, vol. 6,
no. 6, pp. 1286–1300.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee
WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW, 2016. The 2016 World
Health Organization Classifcation of Tumors of the Central Nervous System:
a summary, Acta Neuropathol, vol. 131, no. 6, pp. 803-20.
Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R,
Engebraaten O, 2003. Expression of extracellular matrix components in a
highly infiltrative in vivo glioma model, Acta Neuropathologica, vol. 105, no.
1, pp. 49–57.
Malumbres M, 2014. Cyclin-dependent kinases, Genome Biology, vol. 15, no. 6, p.
122.
65

Maréchal, A. and Zou, L. (2013) ‘DNA damage sensing by the ATM and ATR
kinases’, Cold Spring Harbor Perspectives in Biology, 5(9). doi:
10.1101/cshperspect.a012716.
Matute C, Domercq M, Sánchez-Gómez MV, 2006. Glutamate-mediated glial injury:
Mechanisms and clinical importance, Glia, vol. 53, no. 2, pp. 212–224.

Mcgeachie J, Tennant M, 1997. Growth factors and their implications for clinicians:
A brief review, Australian Dental Journal.
McGirt M, Chaichana KL, Gathinji M, Attenello FJ, Than K, Olivi A, Weingart JD,
Brem H, Quiñones-Hinojosa AR, 2009. Independent association of extent of
resection with survival in patients with malignant brain astrocytoma, J
Neurosurg, vol. 110, no. 1, pp. 156–62.
McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, et
al., 2008. Comprehensive genomic characterization defines human
glioblastoma genes and core pathways, Nature, 455(7216).
Miranda PC, Mekonnen A, Salvador R, Basser PJ, 2014. Predicting the electric field
distribution in the brain for the treatment of glioblastoma, Physics in Medicine
and Biology, vol. 59, no. 15, pp. 4137–4147.
Moorthy R, Rajshekkar V, 2004. Development of glioblastoma, Surg Neurol, vol. 61,
pp. 180–4.
Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker
RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T,
Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M,
Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L,
Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss
S, Wen PY, Willmarth N, Bergman MA, Engh A, 2017. Central nervous
system cancers, version 1.2017 featured updates to the NCCN guidelines,
JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no.
11, pp. 1331–1345.
Nam, T. S. et al. (2011) ‘Glioblastoma mimicking herpes simplex encephalitis’,
Journal of Korean Neurosurgical Society, 50(2), pp. 119–122.
Nasmyth K, Peters JM, Uhlmann F, 2000. Splitting the Chromosome: Cutting the
Ties That Bind Sister Chromatids, Science, vol. 288, no. 5470, pp. 1379–
1384.
Newton HB, 2016. Overview of Brain Tumor Epidemiology, in Newton HB (ed.),
Handbook of Neuro-Oncology Neuroimaging, 2nd edn. Academic Press, New
York.
Noch E, Khalili K, 2009. Molecular mechanisms of necrosis in glioblastoma: The
role of glutamate excitotoxicity, Cancer Biology and Therapy, vol. 8, no. 19,
pp. 1791–1797.
Novocure, 2019. How Optune Works, diakses pada 15 September 2019,
<https://www.optune.com/discover-optune/how-optune-works>.
Oeckinghaus A, Ghosh S, 2009. The NF-kappaB family of transcription factors and
its regulation, Cold Spring Harb Perspect Biol, vol. 1, no. 4, pp. a000034.
66

Ohgaki H, Kleihues P, 2005. Population-based studies on incidence, survival rates,

and genetic alterations in astrocytic and oligodendroglial gliomas, Journal of
neuropathology and Experimental Neurology, vol. 64, no. 6, pp. 479.
Omar AI, 2014. Tumor treating field therapy in combination with bevacizumab for
the treatment of recurrent glioblastoma, Journal of visualized experiments :
JoVE, vol. 92, pp. e51638.
Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE,
Kruchko C, Barnholtz-Sloan JS, 2013. CBTRUS statistical report: Primary
brain and central nervous system tumors diagnosed in the United States in
2006-2010, Neuro-oncology, vol. 15 Suppl 2, pp. ii1--56.
Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS, 2018. Adult glioma
incidence and survival by race or ethnicity in the United States from 2000 to
2014, JAMA Oncology, vol. 4, no. 9, pp. 1254–1262.
Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS, 2018.
CBTRUS Statistical Report: Primary Brain and Other Central Nervous
System Tumors Diagnosed in the United States in 2011-2015, Neuro Oncol,
vol. 20, pp. Suppl 4:iv1.
Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G, 1992. Cyclin A is required
at two points in the human cell cycle, The EMBO journal, vol. 11, no. 3, pp.
961–71.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter
H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S,
Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J,
Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner
DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu
VE, Kinzler KW, 2008. An integrated genomic analysis of human
glioblastoma multiforme, Science, vol. 26, no. 321(5897), pp. 1807–12.
Pearson JRD, Regad T, 2017. Targeting cellular pathways in glioblastoma
multiforme, Signal Transduction and Targeted Therapy, vol. 2(June), pp. 1–
11.
Perry A, Wesseling P, 2016. Histologic classification of gliomas, Handbook of
Clinical Neurology, vol. 134, pp. 71-95.
Peters JM, 2006. The anaphase promoting complex/cyclosome: A machine designed
to destroy, Nature Reviews Molecular Cell Biology, pp. 644–656.
Pollard T, Earnshaw W, Lippincott-Schwartz J, Johnson G, 2017. Cell Biology, 3rd
edn, Elsevier, Philadelphia.
Qiu B, Wang Y, Tao J, Wang Y, 2012. Expression and correlation of Bcl-2 with
pathological grades in human glioma stem cells, Oncology reports, vol. 28,
no. 1, pp. 155–60.
Saez C, Japon MA, Ramos-Morales F, Romero F, Segura D, Tortolero MB, Pintor J,
1999. hpttg is over-expressed in pituitary adenomas and other primary
epithelial neoplasias, Oncogene, vol. 18, no. 39, pp. 5473–5476.
Savarraj JP, Kelly KC, DeCoster MA, 2019. Early glioma is associated with
abnormal electrical events in cortical cultures, Medical and Biological
Engineering and Computing, pp. 1645–1656.
67

Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M, 2006. Epidemiology and
molecular pathology of glioma, Nature Clinical Practice Neurology, vol. 2,
no. 9, pp. 494–503.
Seidel S, Garvalov BK, Acker T, 2015. Isolation and Culture of Primary
Glioblastoma Cells from Human Tumor Specimens, Stem Cell Protocols,
Methods in Molecular Biology, vol. 1235, pp. 263–275.
Sharma R, Gaillard F, 2019. Glioblastoma, diunduh pada 15 September 2019
<https://radiopaedia.org/articles/glioblastoma>.
Shimizu S, Narita M, Tsujimoto Y, 1999. Bcl-2 family proteins regulate the release
of apoptogenic cytochrome c by the mitochondrial channel VDAC, Nature,
vol. 399, no. 6735, pp. 483–487.
Soucek T, Pusch O, Hengstschläger-Ottnad E, Adams PD, Hengstschläger M, 1997.
Deregulated expression of E2F-1 induces cyclin A- and E-associated kinase
activities independently from cell cycle position, Oncogene, vol. 14, no. 19,
pp. 2251–2257.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger
K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin
SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E,
Mirimanoff RO, European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of
Canada Clinical Trials Group, 2005. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma, N Engl J Med, 352(10), pp. 987–96.
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP,
Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard
HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai
R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y,
Hegi ME, Ram Z, 2015. Maintenance therapy with tumor-Treating fields plus
temozolomide vs temozolomide alone for glioblastoma a randomized clinical
trial, JAMA - Journal of the American Medical Association, vol. 314, no. 23,
pp. 2535–2543.
Sun, S. and Ley, S. (2008) ‘New insights into NF-kappaB regulation and function’,
Trends Immunol, 29(10), pp. 469–78.
Swanson KD, Lok E, Wong ET, 2016. An Overview of Alternating Electric Fields
Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma, Current
neurology and neuroscience reports, vol.16, no. 1, pp. 8.
Taal W, Bromberg JEC, van den Bent MJ, 2015. Chemotherapy in glioma, CNS
Oncology, vol. 4, no. 3, pp. 179–192.
Taruno WP, 2015. Electro-Capacitive Cancer Therapy, diunduh pada 15 September
2019, http://www.c-
techlabs.com/brosur/ECCT_Brosur_Eng_New_Small_2015.pdf
Tencho T, Zachariou A, Wilson R, Ditzel M, Meier P, 2005. IAPs are functionally
non-equivalent and regulate effector caspases through distinct mechanisms,
Nature Cell Biology, vol. 7, no. 1, pp. 70–77.
Thakkar J, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS,
Villano JL, 2014. Epidemiologic and molecular prognostic review of
68

glioblastoma, Cancer Epidemiology Biomarkers and Prevention, vol. 23, no.

10, pp. 1985–1996.
Tyas L, Brophy VA, Pope A, Rivett AJ, Tavare JM, 2000. Rapid caspase-3 activation
during apoptosis revealed using fluorescence-resonance energy transfer,
EMBO Reports, vol. 1, no. 3, pp. 266–270.
Ulutin C, Fayda M, Aksu G, Cetinayak O, Kuzhan O, Ors F, Beyzadeoglu M, 2006.
Primary glioblastoma multiforme in younger patients: a single-institution
experience, Tumori, vol. 92, no. 5, pp. 407–11.
Urbanska K, Sokolowska J, Szmidt M, Sysa P, 2014. Glioblastoma multiforme - An
overview, Contemp Oncol (Pozn), vol. 18, no. 5, pp. 307–312.
Valdés-Rives SA, Casique-Aguirre D, German-Castelan L, Velasco-Velazquez MA,
Gonzalez-Arenas A, 2017.Apoptotic Signaling Pathways in Glioblastoma and
Therapeutic Implications, BioMed Research International, pp. 1-12.
De Vries GH, Boullerne AI, 2010. Glial cell lines: An overview, Neurochemical
Research, vol. 35, no. 12, pp. 1978–2000.
Walker AJ, Card T, Bates TE, Muir K, 2011. Tricyclic antidepressants and the
incidence of certain cancers: A study using the GPRD, British Journal of
Cancer, vol. 104, no. 1, pp. 193–197.
Wesseling P, Capper D, 2018. WHO 2016 Classification of gliomas, Neuropathology
and Applied Neurobiology, vol. 44, no. 2, pp. 139–150.
Wilson T, Karajannis M, Harter D, 2014. Glioblastoma multiforme: State of the art
and future therapeutics, Surg Neurol Int, vol. 5, no. 1, pp. 64.
Winn H, 2017. Youmans & Winn Neurological Surgery. 7th edn. Philadelphia:
Elsevier.
Yam CH, Fung TK, Poon RYC, 2002. Cyclin A in cell cycle control and cancer,
Cellular and Molecular Life Sciences, pp. 1317–1326.
Yanagida M, 2014. The role of model organisms in the history of mitosis research,
Cold Spring Harbor Perspectives in Biology, vol. 6, no. 9, pp. 1–14.
Young RM, Jamshidi A, Davis G, Sherman JH, 2015. Current trends in the surgical
management and treatment of adult glioblastoma, Ann Transl Med, vol. 3, no.
9, pp. 121.
Zamorano S, Rojas-Rivera D, Lisbona F, Parra V, Court FA, Villegas R, Cheng EH,
Korsmeyer SJ, Lavandero S, Hetz C, 2012. A BAX/BAK and cyclophilin D-
independent intrinsic apoptosis pathway, PLoS ONE, vol. 7, no. 6, pp. e
37782.
Zhan Y, Carrington EM, Zhang Y, Heinzel S, Lew AM, 2017. Life and death of
activated T cells: How are they different from naïve T Cells?, Frontiers in
Immunology, vol. 8(dec), pp. 1–9.
Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD,
Melmed S, 1999. Structure, Expression, and Function of Human Pituitary
Tumor-Transforming Gene (PTTG), Molecular Endocrinology, vol. 13, no. 1,
pp. 156–166.
Zhang Y, Dube C, Gibert M Jr, Cruickshanks N, Wang B, Coughlan M, Yang Y,
Setiady I, Deveau C, Saoud K, Grello C, Oxford M, Yuan F, Abounader R,
2018. The p53 pathway in glioblastoma’, Cancers, vol. 10, no. 9.
69

Zhang YM, Bhavnani BR, 2006. Glutamate-induced apoptosis in neuronal cells is

mediated via caspase-dependent and independent mechanisms involving
calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and
this process is inhibited by equine estrogens, BMC Neuroscience, vol. 7, pp.
1–22.
Zhang Y, Xia Q, Lin J, 2018. Identification of the potential oncogenes in
glioblastoma based on bioinformatic analysis and elucidation of the
underlying mechanisms, Oncology Reports, vol. 40, no. 2, pp. 715–725.
Zheng K, Jensen TP, Savtchenko LP, Levitt JA, Suhling K, Rusakov DA, 2017.
Nanoscale diffusion in the synaptic cleft and beyond measured with time-
resolved fluorescence anisotropy imaging, Scientific Reports, vol.
7(February), pp. 1–10.
Zou H, McGarry TJ, Bernal T, Kirschner MW, 1999. Identification of a Vertebrate
Sister-Chromatid Separation Inhibitor Involved in Transformation and
Tumorigenesis, Science, vol. 285, no. 5426, pp. 418–422.
Zur A, Brandeis M, 2001. Securin degradation is mediated by fzy and fzr, and is
required for complete chromatid separation but not for cytokinesis, The
EMBO journal, vol. 20, no. 4, pp. 792–801.